Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Oppenheimer
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout
Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...
Q1 EPS Forecast for Nektar Therapeutics Boosted by Analyst
Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright ...
Fintel on MSN4d
Oppenheimer Upgrades Nektar Therapeutics (NKTR)
Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
Nektar upgraded to Outperform at Oppenheimer ahead of rezpeg readout in June
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
Nektar up 12% to 91c after Oppenheimer upgrade with $6 target
EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...
WTOP News6d
Nektar: Q4 Earnings Snapshot
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...